within Pharmacolibrary.Drugs.ATC.J;

model J01DE02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.008199999999999999,
    k12             = 9.6,
    k21             = 9.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DE02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cefpirome is a fourth-generation cephalosporin antibiotic that is used to treat severe bacterial infections including those caused by Gram-negative and some Gram-positive organisms. It is administered intravenously, primarily in hospital settings for complicated infections. Although widely used in some regions, in others its clinical use is limited or discontinued.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single intravenous infusion.</p><h4>References</h4><ol><li><p>Nakayama, I, et al., &amp; Takase, K (1992). Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers. <i>Journal of clinical pharmacology</i> 32(3) 256–266. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1992.tb03834.x\">10.1002/j.1552-4604.1992.tb03834.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1564130/\">https://pubmed.ncbi.nlm.nih.gov/1564130</a></p></li><li><p>Strenkoski, LC, &amp; Nix, DE (1993). Cefpirome clinical pharmacokinetics. <i>Clinical pharmacokinetics</i> 25(4) 263–273. DOI:<a href=\"https://doi.org/10.2165/00003088-199325040-00002\">10.2165/00003088-199325040-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8261711/\">https://pubmed.ncbi.nlm.nih.gov/8261711</a></p></li><li><p>Kang, S, et al., &amp; Chang, MJ (2020). Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation. <i>Antimicrobial agents and chemotherapy</i> 64(5) –. DOI:<a href=\"https://doi.org/10.1128/AAC.00249-20\">10.1128/AAC.00249-20</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32122899/\">https://pubmed.ncbi.nlm.nih.gov/32122899</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DE02;
